地中海贫血市场, [By Thalassemia Type (Alpha Thalassemia, Beta Thalassemia), By Therapeutic Class (Iron Chelating Drugs, Gene Therapy), By End Use (Hospital, Research Institute, Laboratories, Clinics)]; and Geography - Trend, Analysis and Forecast till 2025

报告摘要

The global thalassemia market is anticipated to gain traction due to the factors such as rising funding for developing new combination drugs that act effectively for treating thalassemia.

地中海贫血是一种遗传性血液病，其特点是血红蛋白生成异常，导致贫血。贫血导致皮肤苍白/发黄、乏力、脾脏肿大和尿黑。在地中海贫血中，有助于血红蛋白生成的突变基因从父母转移到孩子身上。地中海贫血一般有两种类型：α地中海贫血和β地中海贫血。β地中海贫血是最常见的地中海贫血类型，其治疗取决于地中海贫血的严重程度。此外，孕妇携带受累胎儿，造成分娩并发症。地中海贫血的常用治疗方法是输血、叶酸和铁螯合。此外，有时骨髓移植是治疗的选择。

根据疾病预防控制中心的数据，全球约有5%的人口，即每10000人中就有4.4人患有地中海贫血。另一方面，越来越多的临床试验用于开发各种生物疗法和基因疗法，有效地治疗地中海贫血，以促进整个行业的研究。此外，地中海贫血国际联合会报告，全球约7%的人口患有与血红蛋白有关的疾病。与世界其他地区相比，希腊、意大利、地中海群岛和东南亚等地区的地中海贫血患病率较高。

地中海贫血新疗法的不断研发，关键参与者研发资金的增加，将支持全球地中海贫血市场的增长。

The global thalassemia market is primarily driven by the factors such as growing number of patients from all age group suffering from thalassemia. Additionally, continuously evolving drug pipeline and increasing number of patented drugs for treating thalassemia would also spur the entire thalassemia treatment industry. Moreover, increasing investment on healthcare infrastructure in the developing countries would also grow the thalassemia market in the near future.

While, increasing number of clinical trials for developing new combination drugs along with the strong, and growing R&D funding and investments on healthcare by the governments of developing and developed economies, and unmet needs for effective treatments influence the market growth during the forecast period.

此外，主要趋势包括药物管道的增加、基因治疗范围的增加和地中海贫血患者人数的增加，促进了地中海贫血市场的增长。然而，严格的监管政策和高昂的治疗费用将阻碍预测期内地中海贫血市场的增长。

Global Thalassemia Market Taxonomy

The global thalassemia market is segmented on the basis of thalassemia type, therapeutic class, end use and geography.

根据地中海贫血的类型，地中海贫血市场分为：

• α地中海贫血
• β地中海贫血

On the basis of therapeutic class, thalassemia market is segmented into:

• Iron Chelating Drugs
• Gene Therapy

On the basis of end use type, thalassemia market is segmented into:

• Hospital
• 研究所
• 实验室
• Clinics

在地理上，地中海贫血市场分为北美、欧洲、亚太地区、拉丁美洲、中东和非洲。提高对地中海贫血的认识，加大政府支持基因治疗的力度，引领北美全球地中海贫血市场。

从地理上看，全球地中海贫血市场将分为北美、欧洲、亚太地区、拉丁美洲和中东以及非洲。预计在预测期内，北美将主导全球地中海贫血市场。由于主要参与者和政府不断增加的研发投资，以及越来越多的主要参与者在该地区投资，北美在技术发展方面占据了主要份额。此外，美国地中海贫血患者数量的增加将刺激北美市场的增长。此外，在预测期内，欧洲的增长速度更快，其次是北美和亚太地区。欧洲国家的增长是血红蛋白病的高发病率，以及人们对这种疾病的认识。

然而,亚太地区也估计crative market during the forecast period. Increasing number of patients suffering from thalassemia and increased government expenditure for developing healthcare infrastructure are the major factors that anticipate governing the thalassemia market in Asia Pacific during coming years.

全球地中海贫血市场的主要参与者包括：

• 蓝鸟生物公司。
• Acceleron制药公司。
• 葛兰素史克公司。
• La Jolla Pharmaceutical Company
• Incyte公司
• 离子制药
• 凯迪斯制药公司
• 桑加莫生物科学
• Lonza Group Ltd.